Tenon Medical, INC

Tenon Medical, Inc. announced the results of its 2026 Annual Meeting of Stockholders, where shareholders approved several critical proposals including a reverse stock split and auditor ratification.

Tenon Medical announced it has received notice from Nasdaq confirming it has regained compliance with the minimum stockholders equity requirement, following a recent public offering.

Tenon Medical, Inc. announced it believes it has regained compliance with Nasdaq's minimum stockholders equity requirement following a recent public offering.

Tenon Medical has implemented a 2026 executive compensation plan and extended the consulting agreement for its Executive Chairman.

Tenon Medical, Inc. has received a notice from Nasdaq indicating non-compliance with the minimum stockholders' equity requirement for continued listing.

Tenon Medical announced a 90% revenue increase and significant gross margin expansion in Q1 2026, alongside a $4.3 million convertible note financing.

Tenon Medical reports increased Q3 revenue and gross profit, but ongoing net losses and significant cash burn raise going concern doubts, partially offset by recent acquisitions and a new PIPE financing.

Tenon Medical, Inc. reported a significant decline in Q2 revenue and gross profit, alongside a reduced net loss, but disclosed substantial doubt about its ability to continue as a going concern and identified material internal control weaknesses.

Tenon Medical's Q1 2025 shows a slight revenue increase but continued net losses, with the company actively pursuing additional financing.

Tenon Medical's Q3 2024 results show a decrease in revenue compared to the same period last year, alongside a reduction in operating expenses, as the company navigates a sales restructuring and reimbursement challenges.

Tenon Medical's Q2 2024 results show increased revenue and gross profit, but the company continues to operate at a loss and faces going concern uncertainty.

Tenon Medical's first quarter 2024 results show a significant increase in revenue, driven by a 42% rise in surgical procedures using their Catamaran System, despite ongoing losses and concerns about their ability to continue as a going concern.

Tenon Medical, Inc. reported increased revenue for 2025 but continues to face significant operating losses, a going concern doubt, and a Nasdaq delisting notice due to its low bid price.

Tenon Medical's 10-K filing reveals a focus on commercial expansion, product development, and addressing financial challenges to sustain operations and achieve profitability in the SI-Joint fusion market.

Tenon Medical, Inc.'s 10-K filing details the company's securities, financial performance, and risk factors, highlighting its focus on the Catamaran SI Joint Fusion System.

Robert K Weigle, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Kristine M Jacques, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Ivan Howard, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Stephen Hochschuler, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Richard Ferrari, a Director of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Kevin Williamson, Chief Financial Officer of Tenon Medical, Inc., reported multiple transactions in common stock on July 31, 2026.

Tenon Medical, Inc. announced its adjourned Annual Meeting will be held virtually on September 18, 2025, to vote on director elections, warrant exercisability, and an equity plan amendment.

Tenon Medical, Inc. has announced its 2025 Annual Meeting of Stockholders, where key proposals include the election of directors, approval of new warrants from a recent inducement transaction, and a significant increase in the company's equity incentive plan share reserve.

Tenon Medical has amended its proxy statement to correct an error regarding the liquidation preference of its Series B Preferred Stock.

Tenon Medical has amended its proxy statement to correct an error regarding the liquidation preference of its Series B Preferred Stock.

Tenon Medical is holding its 2024 Annual Meeting of Stockholders to vote on key proposals including the election of directors, approval of amendments to the equity incentive plan, and compliance with Nasdaq listing rules.

Tenon Medical, Inc. has filed an S-1MEF registration statement to increase the proposed maximum aggregate offering price of its securities by $443,800.

Tenon Medical, Inc. filed an amendment to its S-1 registration statement to offer common stock and warrants to raise capital for operations and debt repayment.

Tenon Medical is registering for the resale of up to 5,673,550 shares of common stock by a selling stockholder, stemming from the exercise of various series of warrants.

Tenon Medical, Inc. files an amendment to its Form S-1 registration statement related to the resale of common stock and the exercise of warrants.

Tenon Medical is registering the resale of up to 2.4 million shares of common stock by a selling stockholder after a warrant inducement offer.

Tenon Medical, Inc. files an amendment to its Form S-1 registration statement to include the form of a Securities Purchase Agreement as an exhibit.

Tenon Medical, Inc. completed the acquisition of SiVantage Inc.'s SImmetry business and SIMPL Medical, LLC's SIMPL business, expanding its sacropelvic fixation and fusion product lines.

Intracoastal Capital LLC, along with individuals Mitchell P. Kopin and Daniel B. Asher, has disclosed a beneficial ownership stake of 4.99% in Tenon Medical, Inc. following a securities purchase agreement.